All In Biotech

Drug Trial Radar · NCT07885293

A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

A Phase III, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of Oral HS-10382 Compared With Investigator-selected Tyrosine Kinase Inhibitors (TKIs) in Adult Patients With Newly Diagnosed Philadelphia Chromosome-positive Chronic-phase Chronic Myeloid Leukemia.

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 408 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

408

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Jul 2029

Study completion Jun 2033

Sponsor

Sponsor type
Industry
First posted
Oct 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a multicenter, open label, randomized phase III clinical study that evaluates the efficacy of oral HS-10382 versus investigator selected TKIs (imatinib, nilotinib, dasatinib, and flumatinib) in newly diagnosed Ph+CML-CP adult participants. The TKI drug chosen by the investigators is the FDA/NMPA approved CML-CP first-line treatment drug: imatinib or nilotinib or dasatinib or flumatinib.

Conditions

  • Chronic Myeloid Leukemia

Interventions

  • HS-10382Drug

    Comes in 40 mg tablets and taken orally

  • ImatinibDrug

    Comes in 100 mg tablets and taken orally

  • DasatinibDrug

    Comes in 20 mg, 50 mg and 70 mg tablets and taken orally

  • NilotinibDrug

    Comes in 150 mg capsules and taken orally

  • FlumatinibDrug

    Comes in 0.2 g tablets and taken orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Major Molecular Response (MMR) at Week 48Time frame: At Week 48

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.